Forecast on China Recombinant Factor Ⅷ Market, [2010-2019]

Forecaste on China Recombinant Factor Ⅷ Market [2010-2019]

Bharat Book Bureau provides the report, on “Forecast on China Recombinant Factor Ⅷ Market, [2010-2019] ” The report provides a basic overview of The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor while over half are in severe conditions. https://www.bharatbook.com/drugs-market-research-reports-667962/investigation-recombinant-china.html

16th Dec 2015- Mumbai, India: Bharatbook.com announces a report on “Forecast on China Recombinant Factor Ⅷ Market [2010-2019] ” The report Explained the points The Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market.

Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor or though not rare, which affects mostly males. Hemophilia A (clotting factor deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor while over half are in severe conditions.

Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor too.

After entering China, recombinant factor develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently,...